Hiromichi Nishimura
Saga Group
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hiromichi Nishimura.
Journal of Acquired Immune Deficiency Syndromes | 1996
Hirokuni Taguchi; Kenichiro Kinoshita; Kiyoshi Takatsuki; Masao Tomonaga; Koichi Araki; Naomichi Arima; Shu-ichi Ikeda; Koji Uozumi; Hidehisa Kohno; Fumio Kawano; Hiroshi Kikuchi; Hironori Takahashi; Kazuo Tamura; Shin Chiyoda; Hiroyuki Tsuda; Hiromichi Nishimura; Takafumi Hosokawa; Hiromitsu Matsuzaki; Saburo Momita; Osamu Yamada; Isao Miyoshi
SUMMARY An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in adult T-cell leukemia/lymphoma (ATLL) patients in a multiinstitutional, cooperative study. Vincristine 1 mg/m2 i.v. day 1, Adriamycin 40 mg/m2 i.v. day 1, cyclophosphamide 400 mg/m2 i.v. day 1, prednisolone 40 mg/m2 i.v. days 1 to 3 and 8 to 10, etoposide 35 mg/m2 i.v. days 1 to 8, vindesine 2 mg/m2 i.v. day 8, ranimustine 50 mg/m2 i.v. day 8, mitoxantrone 7 mg/m2 i.v. day 8, and G-CSF 50 mg/m2 s.c. days 9 to 21 were given for 2 to 4 courses every 3 weeks to 83 patients with ATLL. Complete remission (CR) and partial remission (PR) were achieved in 35.8 and 38.3 percent, respectively, of 81 evaluable patients. The median survival of all patients was 8.5 months, with a predicted 3-year survival of 13.5 percent by the Kaplan-Meier method. The median duration of response was 7.6 months (range 0.2-42.7), and 13 patients were alive. Their median survival time was 29.1 months (range 19.2-44.7). In 67.6 percent of courses, white blood cell (WBC) nadirs were < 1.0 x 10(9)/L. Days required for the recovery of WBC from the nadir to > 1.0 x 10(9)/L were <5 days in 71.4 percent of the treatment courses. The G-CSF supported an intensified chemotherapy regimen for ATLL and yielded better response rate and longer survival compared to previous reports in Japan. Because duration of remission is still short, further studies of postremission therapy or other strategies are warranted.
Cancer | 1985
Yuichi Miyamoto; Kazunari Yamaguchi; Hiromichi Nishimura; Kiyoshi Takatsuki; Tadashi Motoori; Minoru Morimatsu; Tatsuomi Yasaka; Ippei Ohya; Teruto Koga
Two siblings who developed adult T‐cell leukemia (ATL) are presented. The patient and 7 of 26 healthy family members examined had the serum antibodies against ATL‐associated antigens (ATLA). This family study shows that two main routes of transmission of human T‐cell leukemia virus (HTLV) may be involved: one is the route from parents to children and the other is horizontal transmission among spouses, especially from husband to wife; the anti‐ATLA‐positive family is considered to be a high‐risk group for ATL.
Blood | 1983
Kazunari Yamaguchi; Hiromichi Nishimura; H Kohrogi; M Jono; Y Miyamoto; Kiyoshi Takatsuki
Blood | 1984
Kazunari Yamaguchi; Motoharu Seiki; Minoru Yoshida; Hiromichi Nishimura; Fumio Kawano; Kiyoshi Takatsuki
Cancer Research | 1985
Kiyoshi Takatsuki; Kazunari Yamaguchi; Fumio Kawano; Toshio Hattori; Hiromichi Nishimura; Hiroyuki Tsuda; Isao Sanada; Kiyonobu Nakada; Yayeko Itai
Blood | 1985
Isao Sanada; R Tanaka; E Kumagai; Hiroyuki Tsuda; Hiromichi Nishimura; Kazunari Yamaguchi; Fumio Kawano; H Fujiwara; Kiyoshi Takatsuki
Cancer Research | 1989
Tetsuyuki Kiyokawa; K. Shirono; Toshio Hattori; Hiromichi Nishimura; Kazunari Yamaguchi; J. C. Nichols; T. B. Strom; John R. Murphy; Kiyoshi Takatsuki
Blood | 1989
Kenji Shirono; Toshio Hattori; Hiroyuki Hata; Hiromichi Nishimura; Kiyoshi Takatsuki
Cancer | 1984
Fumio Kawano; Hiroyukl Tsuda; Kazunari Yamaguchi; Hiromichi Nishimura; Isao Sanada; Hiromitsu Matsuzaki; Masao Ishii; Kiyoshi Takatsuki
Japanese Journal of Clinical Oncology | 1984
Chisa Taniguchi; Kazunari Yamaguchi; Ritsuko Yoshioka; Nobuhide Takifuji; Kaoru Matsui; Hiromichi Nishimura; Shinhachiro Tomino; Kiyoshi Takatsuki; Ryuji Tanaka